MedTrace Logo

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

NCT06220773 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2024-05-22

No results posted yet for this study

Summary

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

Conditions

Interventions

DRUG

BR1019A

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019A-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019B-1

Subjects take the investigational products once a day for 12 weeks.

DRUG

BR1019C-1

Subjects take the investigational products once a day for 12 weeks.

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-21
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06220773 on ClinicalTrials.gov